“The Role of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment of Heart Failure in Patients with Type 2 Diabetes Mellitus” (2022) Actual Problems of Medicine and Pharmacy, 3(1), pp. 1–10. doi:10.52914/apmp.v3i1.42.